Last reviewed · How we verify

Xcopri — Competitive Intelligence Brief

Xcopri (CENOBAMATE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed Gamma-aminobutyric acid receptor subunit alpha-4 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Xcopri (CENOBAMATE) — Sk Life. Xcopri works by enhancing the activity of a neurotransmitter called GABA, which helps calm down abnormal electrical activity in the brain.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xcopri TARGET CENOBAMATE Sk Life marketed Gamma-aminobutyric acid receptor subunit alpha-4 2019-01-01
Xcopri Xcopri SK Life Science, Inc. marketed Gamma-aminobutyric acid receptor subunit alpha-4, Gamma-aminobutyric acid receptor subunit alpha-6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xcopri — Competitive Intelligence Brief. https://druglandscape.com/ci/cenobamate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: